<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062918" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of nasopharyngeal cancer.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">Nasopharyngeal Cancer (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000038904">nasopharyngeal cancer</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Nasopharyngeal Cancer Treatment (PDQ®)</SummaryTitle><AltTitle TitleType="Short">Nasopharyngeal Cancer Treatment</AltTitle><SummarySection id="_163"><SectMetaData><SpecificDiagnosis ref="CDR0000038904">nasopharyngeal cancer</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Nasopharyngeal Cancer</Title><SummarySection id="_156"><Title>Anatomy</Title></SummarySection><Para id="_2">The nasopharynx has a cuboidal shape.  The lateral walls are formed by the
eustachian tube and the fossa of Rosenmuller.  The roof, sloping downward from
anterior to posterior, is bordered by the pharyngeal hypophysis, pharyngeal
tonsil, and pharyngeal bursa with the base of the skull above.  Anteriorly, the
nasopharynx abuts the posterior choanae and nasal cavity, and the posterior
boundary is formed by the muscles of the posterior pharyngeal wall. 
Inferiorly, the nasopharynx ends at an imaginary horizontal line formed by the
upper surface of the soft palate and the posterior pharyngeal wall.
</Para><SummarySection id="_128"><Title>Risk Factors</Title><Para id="_3">Unlike other squamous cell cancers of the head and neck, nasopharyngeal cancer
does not appear to be linked to excess use of tobacco or moderate alcohol intake (up to 15 drinks a week).  Factors
thought to predispose to this tumor include the following: 
</Para><ItemizedList id="_167" Style="bullet"><ListItem>Chinese (or Asian) ancestry.<Reference refidx="1"/></ListItem><ListItem>Epstein-Barr virus (EBV) exposure.</ListItem><ListItem>Unknown factors that result in
very rare familial clusters.<Reference refidx="2"/></ListItem><ListItem>Heavy alcohol intake.<Reference refidx="3"/></ListItem></ItemizedList></SummarySection><SummarySection id="_129"><Title>Signs and Symptoms</Title><Para id="_4">Symptoms and signs at presentation include the following: 
</Para><ItemizedList id="_130" Style="bullet"><ListItem>Painless, enlarged lymph nodes in
the neck (present in approximately 75% of patients and often bilateral and
posterior).</ListItem><ListItem>Nasal obstruction.</ListItem><ListItem>Epistaxis.</ListItem><ListItem>Diminished hearing.</ListItem><ListItem>Tinnitus.</ListItem><ListItem>Recurrent otitis media.</ListItem><ListItem>Cranial nerve dysfunction (usually II–VI or IX–XII).</ListItem><ListItem>Sore throat.</ListItem><ListItem>Headache.</ListItem></ItemizedList><Para id="_131">In the patient who presents with only cervical
adenopathy, the finding of EBV genomic material in the tissue after
amplification of DNA with the polymerase chain reaction lends strong evidence
for a nasopharyngeal primary tumor, and a concerted search should be conducted
in that area.<Reference refidx="4"/></Para></SummarySection><SummarySection id="_132"><Title>Diagnostic Tests</Title><Para id="_6">Diagnosis is made by biopsy of the nasopharyngeal mass.  Workup includes the following:<Reference refidx="5"/>
</Para><ItemizedList id="_133" Style="bullet"><ListItem>Careful visual examination (by fiberoptic endoscopic examination or examination under anesthesia [EUA]). </ListItem><ListItem>Documentation
of the size and location of the tumor and neck nodes. </ListItem><ListItem>Evaluation of cranial
nerve function including neuro-ophthalmological evaluation and audiological evaluation.</ListItem><ListItem>Computed tomographic (CT) scan or positron emission tomography (PET)-CT scan.</ListItem><ListItem>Magnetic
resonance imaging (MRI) to evaluate skull base invasion. </ListItem><ListItem>Hemogram. </ListItem><ListItem>Chemistry panel.</ListItem><ListItem>Epstein-Barr virus titers.</ListItem></ItemizedList><Para id="_134">Any clinical or
laboratory suggestion of distant metastasis may prompt further evaluation of
other sites.  Careful dental and oral hygiene evaluation and therapy is
particularly important prior to initiation of radiation treatment.  MRI is
often more helpful than CT scans in assessing skull base involvement and in defining
the   extent of abnormalities detected.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/></Para></SummarySection><SummarySection id="_139"><Title>Prognosis</Title><Para id="_7">Major prognostic factors adversely influencing outcome of treatment include the following:<Reference refidx="8"/>
</Para><ItemizedList id="_136" Style="bullet"><ListItem>Large tumor size.<Reference refidx="9"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>]</ListItem><ListItem>A higher tumor (T) stage.</ListItem><ListItem>The presence of involved neck
nodes.</ListItem></ItemizedList><Para id="_137">  Other factors linked to diminished survival that were present in some, but not all,
studies include the following: </Para><ItemizedList id="_138" Style="bullet"><ListItem>Age. </ListItem><ListItem>World Health Organization (WHO) grade I.</ListItem><ListItem>Long interval between
biopsy and initiation of radiation therapy. 
</ListItem><ListItem>Diminished immune function at
diagnosis. </ListItem><ListItem>Incomplete excision of involved neck nodes. </ListItem><ListItem>Pregnancy during
treatment. </ListItem><ListItem>Locoregional relapse. </ListItem><ListItem>Certain EBV antibody titer patterns.</ListItem></ItemizedList><Para id="_8">Small cancers of the nasopharynx are highly curable by radiation therapy, and patients with these small cancers have shown
survival rates of 80% to 90%.<Reference refidx="10"/>
</Para><Para id="_9">Moderately advanced lesions without clinical evidence of spread to cervical
lymph nodes are often curable, and patients with these lesions have shown  survival rates of 50% to 70%.
</Para></SummarySection><SummarySection id="_140"><Title>Follow-up</Title><Para id="_12">Follow-up for patients includes the following: 
</Para><ItemizedList id="_141" Style="bullet"><ListItem>Routine periodic examination of the original
tumor site and neck.</ListItem><ListItem>CT or PET-CT scan.</ListItem><ListItem>MRI scan.</ListItem><ListItem> Blood work.</ListItem><ListItem>EBV titers.</ListItem></ItemizedList><Para id="_142">  Monitoring
of patients should include the following:</Para><ItemizedList id="_143" Style="bullet"><ListItem>Surveillance of thyroid and pituitary function.
</ListItem><ListItem>Dental and oral hygiene.</ListItem><ListItem>Jaw exercises to avoid trismus. </ListItem><ListItem>Evaluation of cranial
nerve function, especially as it relates to vision and hearing. </ListItem><ListItem>Evaluation
of systemic complaints to identify distant metastasis.</ListItem></ItemizedList><Para id="_144">Although most recurrences occur within 5 years of diagnosis, relapse can be
seen at longer intervals.  The incidence of second primary malignancies is
less than after treatment of tumors at other head and neck sites.<Reference refidx="11"/></Para><Para id="_13">Poorly differentiated squamous  cell cancer has been associated with EBV
antibodies.<Reference refidx="4"/><Reference refidx="12"/>  High-titer antibodies to virus capsid antigen and early
antigen, especially of high IgA class, or high titers that persist after
therapy, have been associated with a poorer prognosis.<Reference refidx="13"/>  This finding remains
under evaluation.
</Para><Para id="_5">Tumors of many histologies can occur in the nasopharynx, but this discussion,
like the American Joint Committee on Cancer nasopharynx staging, refers
exclusively to WHO grade I-, II-, and III-type nasopharyngeal carcinoma.
</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="11756578" MedlineID="21630064">Chien YC, Chen JY, Liu MY, et al.: Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 345 (26): 1877-82, 2001.</Citation><Citation idx="2" PMID="7040958" MedlineID="82173026">Decker J, Goldstein JC: Risk factors in head and neck cancer. N Engl J Med 306 (19): 1151-5, 1982.</Citation><Citation idx="3" PMID="19116871">Chen L, Gallicchio L, Boyd-Lindsley K, et al.: Alcohol consumption and the risk of nasopharyngeal carcinoma: a systematic review. Nutr Cancer 61 (1): 1-15, 2009.</Citation><Citation idx="4" PMID="1309196" MedlineID="92072651">Feinmesser R, Miyazaki I, Cheung R, et al.: Diagnosis of nasopharyngeal carcinoma by DNA amplification of tissue obtained by fine-needle aspiration. N Engl J Med 326 (1): 17-21, 1992.</Citation><Citation idx="5">Cummings CW, Fredrickson JM, Harker LA, et al.: Otolaryngology - Head and Neck Surgery. Saint Louis, Mo: Mosby-Year Book, Inc., 1998.</Citation><Citation idx="6">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="7">Laramore GE, ed.: Radiation Therapy of Head and Neck Cancer. Berlin: Springer-Verlag, 1989.</Citation><Citation idx="8" PMID="9169804" MedlineID="97313200">Sanguineti G, Geara FB, Garden AS, et al.: Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys 37 (5): 985-96, 1997.</Citation><Citation idx="9" PMID="20222940">Lee CC, Huang TT, Lee MS, et al.: Clinical application of tumor volume in advanced nasopharyngeal carcinoma to predict outcome. Radiat Oncol 5: 20, 2010.</Citation><Citation idx="10" PMID="1518360" MedlineID="92389717">Bailet JW, Mark RJ, Abemayor E, et al.: Nasopharyngeal carcinoma: treatment results with primary radiation therapy. Laryngoscope 102 (9): 965-72, 1992.</Citation><Citation idx="11" PMID="2001556" MedlineID="91159942">Cooper JS, Scott C, Marcial V, et al.: The relationship of nasopharyngeal carcinomas and second independent malignancies based on the Radiation Therapy Oncology Group experience. Cancer 67 (6): 1673-7, 1991.</Citation><Citation idx="12" PMID="6093669" MedlineID="85045229">Neel HB 3rd, Pearson GR, Taylor WF: Antibodies to Epstein-Barr virus in patients with nasopharyngeal carcinoma and in comparison groups. Ann Otol Rhinol Laryngol 93 (5 Pt 1): 477-82, 1984 Sep-Oct.</Citation><Citation idx="13" PMID="11352952" MedlineID="21251035">Lin JC, Chen KY, Wang WY, et al.: Detection of Epstein-Barr virus DNA the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol 19 (10): 2607-15, 2001.</Citation></ReferenceSection></SummarySection><SummarySection id="_14"><SectMetaData><SpecificDiagnosis ref="CDR0000038904">nasopharyngeal cancer</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Cellular Classification of Nasopharyngeal Cancer</Title><Para id="_15">Although a wide variety of malignant tumors may arise in the nasopharynx, only
squamous cell carcinoma is considered in this discussion because management of
the other types varies substantially with histology.  Subdivisions of squamous cell carcinoma in
this site include the following: 
</Para><Para id="_231">World Health Organization (WHO) histopathological grading system describes three types of nasopharyngeal cancer:</Para><OrderedList id="_232" Style="Arabic"><ListItem>Keratinizing squamous cell carcinoma.</ListItem><ListItem>Nonkeratinizing squamous cell carcinoma.</ListItem><ListItem>Undifferentiated carcinoma (most common subtype).</ListItem></OrderedList><Para id="_233">Previous subdivisions of nasopharyngeal carcinoma included lymphoepithelioma, which is now classified as WHO grade III characterized by lymphoid infiltrate.<Reference refidx="1"/>  </Para><Para id="_234">WHO grade I-type cancer accounts for 20% of cases in United States  and is associated with alcohol and tobacco use; WHO grade II and III represent the endemic form seen in Southern China. </Para><Para id="_147">The presence of keratin has been associated with reduced local
control and survival.</Para><ReferenceSection><Citation idx="1">Shanmugaratnam   K, Sobin  L: Histological Typing of Upper Respiratory Tract Tumours. Geneva: World Health Organization, 1978. International Histologic Classification of Tumours: No. 19.</Citation></ReferenceSection></SummarySection><SummarySection id="_16"><SectMetaData><SpecificDiagnosis ref="CDR0000038904">nasopharyngeal cancer</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for Nasopharyngeal Cancer</Title><Para id="_17">Staging systems are all clinical staging and are  based on the best possible estimate
of the extent of disease before treatment.<Reference refidx="1"/><Reference refidx="2"/>  Assessment of the primary
tumor is based on inspection and palpation, and fiberoptic endoscopic evaluation.  The tumor must be
confirmed histologically, and any other pathologic data obtained on biopsy may
be included.  Evaluation of the function of the cranial nerves is especially
appropriate for tumors of the nasopharynx.  The appropriate nodal drainage
areas are examined by careful palpation and radiologic evaluation.  The retropharyngeal lymph nodes are the first echelon of drainage.<Reference refidx="3"/><Reference refidx="4"/>  Information from diagnostic
imaging studies may be used in staging.  Magnetic resonance imaging provides additional information to computed tomographic scanning in the evaluation of skull base invasion and intracranial spread.<Reference refidx="5"/> Positron emission tomography scans combined with CT are helpful in radiation treatment planning for target delineation of the primary tumor, aids in detection of metastatic nodal involvement and metastatic spread such as lung or skeletal metastases in patients with advanced nasopharyngeal cancer.<Reference refidx="6"/>
</Para><Para id="_18">If a patient has a relapse, a complete reassessment must be done to select the
appropriate additional therapy.
</Para><SummarySection id="_219"><Title>Definitions of TNM</Title><Para id="_203">The American Joint Committee on Cancer  (AJCC) has designated staging by TNM
classification to define nasopharyngeal cancer.<Reference refidx="7"/>
</Para><Table id="_207"><Title>Table 1.  Primary Tumor (T)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="10.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="90.00%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Pharynx. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 41-56.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>b</Superscript>Parapharyngeal extension denotes posterolateral infiltration of tumor.</entry></Row></TFoot><TBody><Row><entry>TX</entry><entry>Primary tumor cannot be assessed.</entry></Row><Row><entry>T0</entry><entry>No evidence of primary tumor.</entry></Row><Row><entry>Tis</entry><entry>Carcinoma <Emphasis>in situ</Emphasis>.</entry></Row><Row><entry>T1</entry><entry>Tumor confined to the nasopharynx, or tumor extends to oropharynx and/or nasal cavity without parapharyngeal extension.<Superscript>b</Superscript></entry></Row><Row><entry>T2</entry><entry>Tumor with parapharyngeal extension.<Superscript>b</Superscript></entry></Row><Row><entry>T3</entry><entry>Tumor involves bony structures of skull base and/or paranasal sinuses.</entry></Row><Row><entry>T4</entry><entry>Tumor with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space.</entry></Row></TBody></TGroup></Table><Table id="_208"><Title>Table 2.  Regional Lymph Nodes (N)<Superscript>a, b</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="10.42%"/><ColSpec ColName="col2" ColNum="2" ColWidth="89.57%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Pharynx. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 44-56.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>b</Superscript>The distribution and the prognostic impact of regional lymph node spread from nasopharyngeal cancer, particularly of the undifferentiated type, are different from those of other head and neck mucosal cancers and justify the use of a different N classification scheme. </entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>c</Superscript>Midline nodes are considered ipsilateral nodes.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>d</Superscript>Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho. It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder. Note that this would include caudal portions of levels IV and VB. All cases with lymph nodes (whole or part) in the fossa are considered N3b.</entry></Row></TFoot><TBody><Row><entry>NX</entry><entry>Regional lymph nodes cannot be assessed.</entry></Row><Row><entry>N0</entry><entry>No regional lymph node metastasis.</entry></Row><Row><entry>N1</entry><entry>Unilateral metastasis in cervical lymph node(s), ≤6 cm in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, ≤6 cm in greatest dimension.<Superscript>c</Superscript></entry></Row><Row><entry>N2</entry><entry>Bilateral metastasis in cervical lymph node(s), ≤6 cm in greatest dimension, above the supraclavicular    fossa.<Superscript>d</Superscript></entry></Row><Row><entry>N3</entry><entry>Metastasis in a lymph node(s)<Superscript>c</Superscript>  &gt;6 cm and/or to supraclavicular fossa.<Superscript>d</Superscript>  </entry></Row><Row><entry>N3a</entry><entry>&gt;6 cm in dimension. </entry></Row><Row><entry>N3b</entry><entry>Extension to the supraclavicular fossa.<Superscript>d</Superscript></entry></Row></TBody></TGroup></Table><Table id="_192"><Title>Table 3.  Distant Metastasis (M)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="7.87%"/><ColSpec ColName="col2" ColNum="2" ColWidth="92.12%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Pharynx. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 41-56.</entry></Row></TFoot><TBody><Row><entry>M0</entry><entry>No distant metastasis.</entry></Row><Row><entry>M1</entry><entry>Distant metastasis.</entry></Row></TBody></TGroup></Table><Table id="_193"><Title>Table 4.  Anatomic Stage/Prognostic Groups<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">T</entry><entry Align="Center">N</entry><entry Align="Center">M</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Pharynx. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp  41-56.</entry></Row></TFoot><TBody><Row><entry>0</entry><entry>Tis</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry> I</entry><entry>T1</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry MoreRows="2"> II</entry><entry>T1</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>T2</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>T2</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry MoreRows="4"> III</entry><entry>T1</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry>T2</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry>T3</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>T3</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>T3</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry MoreRows="2"> IVA</entry><entry>T4</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>T4</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>T4</entry><entry>N2</entry><entry>M0</entry></Row><Row><entry>IVB</entry><entry>Any T</entry><entry>N3</entry><entry>M0</entry></Row><Row><entry>IVC</entry><entry>Any T</entry><entry>Any N</entry><entry>M1</entry></Row></TBody></TGroup></Table></SummarySection><ReferenceSection><Citation idx="1" PMID="1985736" MedlineID="91091779">Teo PM, Leung SF, Yu P, et al.: A comparison of Ho's, International Union Against Cancer, and American Joint Committee stage classifications for nasopharyngeal carcinoma. Cancer 67 (2): 434-9, 1991.</Citation><Citation idx="2" PMID="10096252" MedlineID="99193916">Lee AW, Foo W, Law SC, et al.: Staging of nasopharyngeal carcinoma: from Ho's to the new UICC system. Int J Cancer 84 (2): 179-87, 1999.</Citation><Citation idx="3">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="4">Laramore GE, ed.: Radiation Therapy of Head and Neck Cancer. Berlin: Springer-Verlag, 1989.</Citation><Citation idx="5" PMID="3279242" MedlineID="88155850">Consensus conference. Magnetic resonance imaging. JAMA 259 (14): 2132-8, 1988.</Citation><Citation idx="6" PMID="16446332">Liu FY, Chang JT, Wang HM, et al.: [18F]fluorodeoxyglucose positron emission tomography is more sensitive than skeletal scintigraphy for detecting bone metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 24 (4): 599-604, 2006.</Citation><Citation idx="7">Pharynx. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 41-56.</Citation></ReferenceSection></SummarySection><SummarySection id="_50"><SectMetaData><SpecificDiagnosis ref="CDR0000038904">nasopharyngeal cancer</SpecificDiagnosis><SectionType>Treatment option overview--legacy</SectionType></SectMetaData><Title>Treatment Option Overview</Title><Para id="_168"><Strong>Standard treatments for patients with nasopharyngeal cancer include the following:</Strong></Para><ItemizedList id="_169" Style="bullet"><ListItem>Radiation therapy alone.</ListItem><ListItem>Concurrent chemoradiation followed by adjuvant chemotherapy.</ListItem><ListItem>Surgery for residual nodal disease.</ListItem><ListItem>Chemotherapy alone for metastatic disease.</ListItem></ItemizedList><Para id="_51">High-dose radiation therapy with chemotherapy is the primary treatment of nasopharyngeal cancer,
both for the primary tumor site and the neck.<Reference refidx="1"/>  When feasible, surgery is
usually reserved for nodes that fail to regress after radiation therapy or for nodal recurrence following clinical complete response.  Radiation therapy dose and
field margins are individually tailored to the location and size of the primary
tumor and lymph nodes.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>  Although most tumors are treated with
external-beam radiation therapy (EBRT) exclusively, in some tumors radiation therapy may be
boosted with intracavitary or interstitial implants or by the use of stereotactic radiosurgery when clinical
expertise is available, and the anatomy is suitable.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/>  Intensity-modulated radiation therapy (IMRT) results in a lower incidence of xerostomia and may provide a better quality of life than conventional three-dimensional or two-dimensional radiation therapy.<Reference refidx="11"/><Reference refidx="12"/>[<LOERef href="CDR0000335127">Level of evidence: 1iiC</LOERef>] Results of a phase II RTOG study (<ProtocolRef href="CDR0000269314" nct_id="NCT00057785">RTOG-0225</ProtocolRef>) showed the feasibility of IMRT in a multi-institutional setting and minimal grade III and IV xerostomia rates.<Reference refidx="13"/> The rate of grade 2 xerostomia at 1 year from start of IMRT was 13.5%. Only 2 of 68  patients were reported with  grade 3 xerostomia, and none had grade 4 xerostomia.<Reference refidx="13"/>[<LOERef href="CDR0000335134">Level of evidence: 2C</LOERef>]  
</Para><Para id="_52">Accumulating evidence has demonstrated a high incidence (&gt;30%–40%) of
hypothyroidism in patients who have received radiation therapy that delivered EBRT to the entire thyroid gland or to the pituitary gland. 
Thyroid-function testing of patients should be considered prior to therapy and
as part of posttreatment follow-up.<Reference refidx="14"/><Reference refidx="15"/>
</Para><Para id="_170"><Strong>Treatments under clinical evaluation for patients with nasopharyngeal cancer include the following:</Strong></Para><ItemizedList id="_171" Style="bullet"><ListItem>Dose escalation with new radiation therapy techniques such as stereotactic radiation therapy boost.<Reference refidx="16"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</ListItem><ListItem>Brachytherapy.<Reference refidx="17"/>[<LOERef href="CDR0000335155">Level of evidence: 3iiiDii</LOERef>]</ListItem></ItemizedList><Para id="_172">Information about ongoing clinical trials is available from the <ExternalRef xref="http://cancer.gov/clinicaltrials">NCI
Web site</ExternalRef>.</Para><ReferenceSection><Citation idx="1" PMID="16377415">Baujat B, Audry H, Bourhis J, et al.: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64 (1): 47-56, 2006.</Citation><Citation idx="2" PMID="1587746" MedlineID="92267885">Perez CA, Devineni VR, Marcial-Vega V, et al.: Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys 23 (2): 271-80, 1992.</Citation><Citation idx="3" PMID="8330138" MedlineID="93321014">Lee AW, Law SC, Foo W, et al.: Nasopharyngeal carcinoma: local control by megavoltage irradiation. Br J Radiol 66 (786): 528-36, 1993.</Citation><Citation idx="4" PMID="9165137" MedlineID="97307795">Geara FB, Sanguineti G, Tucker SL, et al.: Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol 43 (1): 53-61, 1997.</Citation><Citation idx="5" PMID="9169804" MedlineID="97313200">Sanguineti G, Geara FB, Garden AS, et al.: Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys 37 (5): 985-96, 1997.</Citation><Citation idx="6">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="7" PMID="1924860" MedlineID="92021574">Itami J, Anzai Y, Nemoto K, et al.: Prognostic factors for local control in nasopharyngeal cancer (NPC): analysis by multivariate proportional hazard models. Radiother Oncol 21 (4): 233-9, 1991.</Citation><Citation idx="8" PMID="9626223" MedlineID="98289463">Levendag PC, Schmitz PI, Jansen PP, et al.: Fractionated high-dose-rate brachytherapy in primary carcinoma of the nasopharynx. J Clin Oncol 16 (6): 2213-20, 1998.</Citation><Citation idx="9" PMID="10661353" MedlineID="20124969">Teo PM, Leung SF, Lee WY, et al.: Intracavitary brachytherapy significantly enhances local control of early T-stage nasopharyngeal carcinoma: the existence of a dose-tumor-control relationship above conventional tumoricidal dose. Int J Radiat Oncol Biol Phys 46 (2): 445-58, 2000.</Citation><Citation idx="10" PMID="12829140">Le QT, Tate D, Koong A, et al.: Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 56 (4): 1046-54, 2003.</Citation><Citation idx="11" PMID="17145528">Pow EH, Kwong DL, McMillan AS, et al.: Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66 (4): 981-91, 2006.</Citation><Citation idx="12" PMID="17971582">Kam MK, Leung SF, Zee B, et al.: Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25 (31): 4873-9, 2007.</Citation><Citation idx="13" PMID="19564532">Lee N, Harris J, Garden AS, et al.: Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 27 (22): 3684-90, 2009.</Citation><Citation idx="14" PMID="7836081" MedlineID="95137798">Turner SL, Tiver KW, Boyages SC: Thyroid dysfunction following radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 31 (2): 279-83, 1995.</Citation><Citation idx="15" PMID="7836099" MedlineID="95137818">Constine LS: What else don't we know about the late effects of radiation in patients treated for head and neck cancer? Int J Radiat Oncol Biol Phys 31 (2): 427-9, 1995.</Citation><Citation idx="16" PMID="10571198">Tate DJ, Adler JR Jr, Chang SD, et al.: Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: impact on local control. Int J Radiat Oncol Biol Phys 45 (4): 915-21, 1999.</Citation><Citation idx="17" PMID="15122654">Lu JJ, Shakespeare TP, Tan LK, et al.: Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma. Head Neck 26 (5): 389-95, 2004.</Citation></ReferenceSection></SummarySection><SummarySection id="_54"><SectMetaData><SpecificDiagnosis ref="CDR0000038905">stage I nasopharyngeal cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage I Nasopharyngeal Cancer</Title><Para id="_55"><Strong>Standard treatment options:</Strong>
</Para><ItemizedList id="_87" Style="bullet"><ListItem>High-dose radiation therapy to the primary tumor site and prophylactic
radiation therapy to the nodal drainage.<Reference refidx="1"/></ListItem></ItemizedList><SummarySection id="_TrialSearch_54_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_54_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38905&amp;tt=1&amp;format=2&amp;cn=1">stage I nasopharyngeal cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_54_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="19231110">Xiao WW, Han F, Lu TX, et al.: Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 74 (4): 1070-6, 2009.</Citation></ReferenceSection></SummarySection><SummarySection id="_57"><SectMetaData><SpecificDiagnosis ref="CDR0000038906">stage II nasopharyngeal cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage II Nasopharyngeal Cancer</Title><Para id="_58"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_88" Style="Arabic" Compact="No"><ListItem>Chemoradiation therapy followed by adjuvant chemotherapy, as was used  in the INT-0099 trial, for example.<Reference refidx="1"/>[<LOERef href="CDR0000335150">Level of evidence: 3iiiA</LOERef>] (Patients with parapharyngeal extension were originally staged as T3 in the INT-0099 study and are now considered T2 in the current staging.)</ListItem><ListItem>High-dose radiation therapy to the primary tumor site and prophylactic
radiation therapy to the nodal drainage.<Reference refidx="2"/>
</ListItem></OrderedList><SummarySection id="_TrialSearch_57_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_57_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38906&amp;tt=1&amp;format=2&amp;cn=1">stage II nasopharyngeal cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_57_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="10811668" MedlineID="20271992">Cheng SH, Tsai SY, Yen KL, et al.: Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol 18 (10): 2040-5, 2000.</Citation><Citation idx="2" PMID="19231110">Xiao WW, Han F, Lu TX, et al.: Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 74 (4): 1070-6, 2009.</Citation></ReferenceSection></SummarySection><SummarySection id="_61"><SectMetaData><SpecificDiagnosis ref="CDR0000038907">stage III nasopharyngeal cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage III Nasopharyngeal Cancer</Title><Para id="_63"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_89" Style="Arabic" Compact="No"><ListItem>Combined chemoradiation therapy.<Reference refidx="1"/><Reference refidx="2"/></ListItem><ListItem>Combined chemoradiation therapy followed by adjuvant chemotherapy, as evidenced in INT-0099, for example.<Reference refidx="3"/><Reference refidx="4"/>
<Reference refidx="2"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/></ListItem><ListItem>Altered fractionation radiation therapy.<Reference refidx="15"/><Reference refidx="16"/>
</ListItem><ListItem>Neck dissection may be indicated for persistent or recurrent nodes if the
primary tumor site is controlled.<Reference refidx="17"/>
</ListItem></OrderedList><Para id="_67"><Strong>Treatment options under clinical evaluation:</Strong>
</Para><ItemizedList id="_90" Style="bullet" Compact="No"><ListItem>Neoadjuvant chemotherapy. Neoadjuvant chemotherapy as given in clinical trials has been used to shrink
tumors, which renders them more definitively treatable with radiation therapy. 
Chemotherapy is given prior to the other modalities, hence the designation
neoadjuvant to distinguish it from standard adjuvant therapy, which is given
after or during definitive therapy with radiation or after surgery.  Many drug
combinations have been used in neoadjuvant chemotherapy.  <Para id="_235">Two randomized,
prospective trials compared combination chemotherapy (i.e., cisplatin, epirubicin,
and bleomycin or cisplatin plus fluorouracil [5-FU] infusion) plus radiation therapy to
radiation therapy alone.<Reference refidx="3"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>];<Reference refidx="18"/>[<LOERef href="CDR0000335129">Level of evidence: 1iiDii</LOERef>]  Although disease-free survival was improved in the chemotherapy group
for both groups, improvement in overall survival was reported only from the
Intergroup trial   in which chemotherapy with cisplatin was ever concurrently given.<Reference refidx="3"/></Para> </ListItem></ItemizedList><Para id="_265">Clinical trials for advanced tumors evaluating the use of chemotherapy before
radiation therapy, concomitant with radiation therapy, or as adjuvant therapy
after radiation therapy should be considered.<Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/></Para><SummarySection id="_TrialSearch_61_sid_7"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_61_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38907&amp;tt=1&amp;format=2&amp;cn=1">stage III nasopharyngeal cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_61_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="15542811">Langendijk JA, Leemans ChR, Buter J, et al.: The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 22 (22): 4604-12, 2004.</Citation><Citation idx="2" PMID="12040275" MedlineID="22034882">Huncharek M, Kupelnick B: Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 25 (3): 219-23, 2002.</Citation><Citation idx="3" PMID="9552031" MedlineID="98211757">Al-Sarraf M, LeBlanc M, Giri PG, et al.: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16 (4): 1310-7, 1998.</Citation><Citation idx="4" PMID="10030248" MedlineID="99153319">Teo PM, Chan AT, Lee WY, et al.: Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. Int J Radiat Oncol Biol Phys 43 (2): 261-71, 1999.</Citation><Citation idx="5" PMID="11956263" MedlineID="21953228">Chan AT, Teo PM, Ngan RK, et al.: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20 (8): 2038-44, 2002.</Citation><Citation idx="6" PMID="15657403">Chua DT, Ma J, Sham JS, et al.: Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 23 (6): 1118-24, 2005.</Citation><Citation idx="7" PMID="16170180">Wee J, Tan EH, Tai BC, et al.: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23 (27): 6730-8, 2005.</Citation><Citation idx="8" PMID="16230677">Zhang L, Zhao C, Peng PJ, et al.: Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 23 (33): 8461-8, 2005.</Citation><Citation idx="9" PMID="16377415">Baujat B, Audry H, Bourhis J, et al.: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64 (1): 47-56, 2006.</Citation><Citation idx="10" PMID="17054200">Baujat B, Audry H, Bourhis J, et al.: Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. Cochrane Database Syst Rev  (4): CD004329, 2006.</Citation><Citation idx="11" PMID="18472356">Chen Y, Liu MZ, Liang SB, et al.: Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 71 (5): 1356-64, 2008.</Citation><Citation idx="12" PMID="20634482">Lee AW, Tung SY, Chua DT, et al.: Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 102 (15): 1188-98, 2010.</Citation><Citation idx="13" PMID="20971520">Lee AW, Tung SY, Chan AT, et al.: A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother Oncol 98 (1): 15-22, 2011.</Citation><Citation idx="14" PMID="21112774">Lee AW, Tung SY, Ngan RK, et al.: Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer 47 (5): 656-66, 2011.</Citation><Citation idx="15" PMID="1571905" MedlineID="92240564">Johnson CR, Schmidt-Ullrich RK, Wazer DE: Concomitant boost technique using accelerated superfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Cancer 69 (11): 2749-54, 1992.</Citation><Citation idx="16" PMID="19451314">Chen CY, Han F, Zhao C, et al.: Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone. Br J Radiol 82 (978): 452-8, 2009.</Citation><Citation idx="17">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="18" PMID="8655368" MedlineID="96272184">Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(&gt; or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 35 (3): 463-9, 1996.</Citation><Citation idx="19" PMID="1382499" MedlineID="93001581">Azli N, Armand JP, Rahal M, et al.: Alternating chemo-radiotherapy with cisplatin and 5-fluorouracil plus bleomycin by continuous infusion for locally advanced undifferentiated carcinoma nasopharyngeal type. Eur J Cancer 28A (11): 1792-7, 1992.</Citation><Citation idx="20" PMID="7558945" MedlineID="96027768">Chan AT, Teo PM, Leung TW, et al.: A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 33 (3): 569-77, 1995.</Citation><Citation idx="21" PMID="8609658" MedlineID="96199879">Merlano M, Benasso M, Corvò R, et al.: Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88 (9): 583-9, 1996.</Citation><Citation idx="22" PMID="10735893" MedlineID="20200498">Jeremic B, Shibamoto Y, Milicic B, et al.: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18 (7): 1458-64, 2000.</Citation></ReferenceSection></SummarySection><SummarySection id="_70"><SectMetaData><SpecificDiagnosis ref="CDR0000038908">stage IV nasopharyngeal cancer</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage IV Nasopharyngeal Cancer</Title><Para id="_72"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_91" Style="Arabic" Compact="No"><ListItem>Chemoradiation therapy followed by adjuvant chemotherapy, as evidenced in INT-0099, for example.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/></ListItem><ListItem>Altered fractionation including hyperfractionated radiation therapy.<Reference refidx="15"/><Reference refidx="16"/>
</ListItem><ListItem>Neck dissection should be reserved for persistent or recurrent nodes.<Reference refidx="17"/></ListItem><ListItem>Chemotherapy for patients with stage IVC disease.<Reference refidx="18"/>
</ListItem></OrderedList><Para id="_77"><Strong>Treatment options under clinical evaluation:</Strong>
</Para><OrderedList id="_262" Style="Arabic" Compact="No">
     <ListItem>Neoadjuvant chemotherapy. Neoadjuvant chemotherapy  has been used to shrink
tumors, which  renders them more definitively treatable with radiation therapy. 
Chemotherapy is given prior to the other modalities, hence the designation
neoadjuvant to distinguish it from standard adjuvant therapy, which is given
after or during definitive therapy with radiation or after surgery.  Many drug
combinations have been used in neoadjuvant chemotherapy.  <Para id="_263">Clinical trials for advanced tumors to evaluate the use of chemotherapy before
radiation therapy, concomitant with radiation therapy, or as adjuvant therapy
after radiation therapy should be considered.<Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/></Para><Para id="_261">A phase II, randomized study of 65 patients with stage III and IV nasopharyngeal carcinoma were randomly assigned to neoadjuvant docetaxel (75 mg/m<Superscript>2</Superscript>) and cisplatin (75 mg/m<Superscript>2</Superscript>) every 3 weeks for two cycles followed by cisplatin (40 mg/m<Superscript>2</Superscript>) every week versus chemoradiation alone.  Rates of grade 3 or 4 neutropenia were 97% during the neoadjuvant arm with no difference in toxicities between the two groups during the chemoradiation portion of treatment.   The 3-year progression-free survival for neoadjuvant docetaxel versus the control arm was 88.2% and 59.5% (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.20–1.19; <Emphasis>P</Emphasis> = .12). The 3-year overall survival for neoadjuvant docetaxel  versus the control arm was 94.1% and 67.7% (HR, 0.24; 95% CI, 0.078–0.73; <Emphasis>P</Emphasis> = .012).<Reference refidx="23"/>[<LOERef href="CDR0000335131">Level of evidence: 1iiDiii</LOERef>] These data have to be confirmed in a definitive phase III trial.</Para><Para id="_264">Three randomized,
prospective trials compared combination chemotherapy (i.e., cisplatin, epirubicin,
and bleomycin or cisplatin plus fluorouracil [5-FU] infusion) plus radiation therapy to
radiation therapy alone.<Reference refidx="1"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]; <Reference refidx="24"/><Reference refidx="25"/>[<LOERef href="CDR0000335129">Level of evidence: 1iiDii</LOERef>]  Although disease-free survival (DFS) was improved in the chemotherapy group
for both groups, improvement in overall survival (OS) was reported only from the
Intergroup trial  in which chemotherapy with cisplatin was ever concurrently given.<Reference refidx="1"/></Para></ListItem><ListItem>Concurrent radiation therapy with chemotherapy. A study of 1,355 patients compared concurrent radiation therapy with carboplatin or cisplatin administered  with 96-hour infusion of 5-FU monthly for three cycles.<Reference refidx="26"/>  The 3-year DFS rate was 63.4% for patients in the cisplatin arm and 60.9% for patients in  the carboplatin arm (<Emphasis>P</Emphasis> = .961; HR, 0.70; 95% CI, 0.50–0.98).  OS rates were 77% for patients in the cisplatin arm and 79% for patients in the carboplatin arm (<Emphasis>P</Emphasis> = .988; HR, 0.83; 95% CI, 0.63–1.010).<Reference refidx="26"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>] Toxicity to kidneys and red blood cell count was greater in patients in the cisplatin group.</ListItem></OrderedList><SummarySection id="_TrialSearch_70_sid_8"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_70_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38908&amp;tt=1&amp;format=2&amp;cn=1">stage IV nasopharyngeal cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_70_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="9552031" MedlineID="98211757">Al-Sarraf M, LeBlanc M, Giri PG, et al.: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16 (4): 1310-7, 1998.</Citation><Citation idx="2" PMID="10030248" MedlineID="99153319">Teo PM, Chan AT, Lee WY, et al.: Enhancement of local control in locally advanced node-positive nasopharyngeal carcinoma by adjunctive chemotherapy. Int J Radiat Oncol Biol Phys 43 (2): 261-71, 1999.</Citation><Citation idx="3" PMID="11956263" MedlineID="21953228">Chan AT, Teo PM, Ngan RK, et al.: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 20 (8): 2038-44, 2002.</Citation><Citation idx="4" PMID="12040275" MedlineID="22034882">Huncharek M, Kupelnick B: Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 25 (3): 219-23, 2002.</Citation><Citation idx="5" PMID="12586799" MedlineID="22474353">Lin JC, Jan JS, Hsu CY, et al.: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21 (4): 631-7, 2003.</Citation><Citation idx="6" PMID="15657403">Chua DT, Ma J, Sham JS, et al.: Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 23 (6): 1118-24, 2005.</Citation><Citation idx="7" PMID="16170180">Wee J, Tan EH, Tai BC, et al.: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23 (27): 6730-8, 2005.</Citation><Citation idx="8" PMID="16230677">Zhang L, Zhao C, Peng PJ, et al.: Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results. J Clin Oncol 23 (33): 8461-8, 2005.</Citation><Citation idx="9" PMID="16377415">Baujat B, Audry H, Bourhis J, et al.: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 64 (1): 47-56, 2006.</Citation><Citation idx="10" PMID="17054200">Baujat B, Audry H, Bourhis J, et al.: Chemotherapy as an adjunct to radiotherapy in locally advanced nasopharyngeal carcinoma. Cochrane Database Syst Rev  (4): CD004329, 2006.</Citation><Citation idx="11" PMID="18472356">Chen Y, Liu MZ, Liang SB, et al.: Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys 71 (5): 1356-64, 2008.</Citation><Citation idx="12" PMID="20634482">Lee AW, Tung SY, Chua DT, et al.: Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 102 (15): 1188-98, 2010.</Citation><Citation idx="13" PMID="20971520">Lee AW, Tung SY, Chan AT, et al.: A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother Oncol 98 (1): 15-22, 2011.</Citation><Citation idx="14" PMID="21112774">Lee AW, Tung SY, Ngan RK, et al.: Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer 47 (5): 656-66, 2011.</Citation><Citation idx="15" PMID="1571905" MedlineID="92240564">Johnson CR, Schmidt-Ullrich RK, Wazer DE: Concomitant boost technique using accelerated superfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Cancer 69 (11): 2749-54, 1992.</Citation><Citation idx="16" PMID="19451314">Chen CY, Han F, Zhao C, et al.: Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone. Br J Radiol 82 (978): 452-8, 2009.</Citation><Citation idx="17">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="18" PMID="12467065" MedlineID="22354014">Ma BB, Tannock IF, Pond GR, et al.: Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer 95 (12): 2516-23, 2002.</Citation><Citation idx="19" PMID="8410119" MedlineID="94015211">Dimery IW, Peters LJ, Goepfert H, et al.: Effectiveness of combined induction chemotherapy and radiotherapy in advanced nasopharyngeal carcinoma. J Clin Oncol 11 (10): 1919-28, 1993.</Citation><Citation idx="20" PMID="7558945" MedlineID="96027768">Chan AT, Teo PM, Leung TW, et al.: A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 33 (3): 569-77, 1995.</Citation><Citation idx="21" PMID="8609658" MedlineID="96199879">Merlano M, Benasso M, Corvò R, et al.: Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88 (9): 583-9, 1996.</Citation><Citation idx="22" PMID="10735893" MedlineID="20200498">Jeremic B, Shibamoto Y, Milicic B, et al.: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18 (7): 1458-64, 2000.</Citation><Citation idx="23" PMID="19064973">Hui EP, Ma BB, Leung SF, et al.: Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 27 (2): 242-9, 2009.</Citation><Citation idx="24" PMID="8655368" MedlineID="96272184">Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(&gt; or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. Int J Radiat Oncol Biol Phys 35 (3): 463-9, 1996.</Citation><Citation idx="25" PMID="16192584">Lee AW, Lau WH, Tung SY, et al.: Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23 (28): 6966-75, 2005.</Citation><Citation idx="26" PMID="17467265">Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al.: Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. Eur J Cancer 43 (9): 1399-406, 2007.</Citation></ReferenceSection></SummarySection><SummarySection id="_80"><SectMetaData><SpecificDiagnosis ref="CDR0000038909">recurrent nasopharyngeal cancer</SpecificDiagnosis><SectionType>Treatment options for recurrent cancer</SectionType></SectMetaData><Title>Recurrent Nasopharyngeal Cancer</Title><Para id="_81"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_93" Style="Arabic" Compact="No"><ListItem>Selected patients with local recurrence may be retreated with moderate-dose external-beam
radiation therapy using intensity-modulated radiation therapy, stereotactic radiation therapy, or intracavitary or interstitial
radiation to the site of recurrence.<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/></ListItem><ListItem>In highly selected patients, surgical resection of locally recurrent lesions may be
considered.
</ListItem><ListItem>If a patient has metastatic disease or local recurrence that is no longer
amenable to surgery or radiation therapy, chemotherapy should be considered.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/></ListItem></OrderedList><Para id="_85"><Strong>Treatment options under clinical evaluation:</Strong>
</Para><ItemizedList id="_94" Style="bullet"><ListItem>Clinical trials evaluating chemotherapy should be
considered.
 </ListItem><ListItem>Stereotactic radiation for locally recurrent disease or persistence.<Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/>[<LOERef href="CDR0000587991">Level of evidence: 3iiiDiv</LOERef>]</ListItem></ItemizedList><SummarySection id="_TrialSearch_80_sid_9"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_80_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38909&amp;tt=1&amp;format=2&amp;cn=1">recurrent nasopharyngeal cancer</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_80_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1">Mendenhall WM, Werning JW, Pfister DG: Treatment of head and neck cancer. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams &amp; Wilkins, 2011, pp 729-80.</Citation><Citation idx="2" PMID="4051112" MedlineID="86023387">Vikram B, Strong EW, Shah JP, et al.: Intraoperative radiotherapy in patients with recurrent head and neck cancer. Am J Surg 150 (4): 485-7, 1985.</Citation><Citation idx="3" PMID="19467802">Koutcher L, Lee N, Zelefsky M, et al.: Reirradiation of locally recurrent nasopharynx cancer with external beam radiotherapy with or without brachytherapy. Int J Radiat Oncol Biol Phys 76 (1): 130-7, 2010.</Citation><Citation idx="4" PMID="3278391" MedlineID="88145720">Al-Sarraf M: Head and neck cancer: chemotherapy concepts. Semin Oncol 15 (1): 70-85, 1988.</Citation><Citation idx="5" PMID="1732427" MedlineID="92121936">Jacobs C, Lyman G, Velez-García E, et al.: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10 (2): 257-63, 1992.</Citation><Citation idx="6" PMID="11865813" MedlineID="21851883">Foo KF, Tan EH, Leong SS, et al.: Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol 13 (1): 150-6, 2002.</Citation><Citation idx="7" PMID="12694836">Chua DT, Sham JS, Kwong PW, et al.: Linear accelerator-based stereotactic radiosurgery for limited, locally persistent, and recurrent nasopharyngeal carcinoma: efficacy and complications. Int J Radiat Oncol Biol Phys 56 (1): 177-83, 2003.</Citation><Citation idx="8" PMID="12203799">Pai PC, Chuang CC, Wei KC, et al.: Stereotactic radiosurgery for locally recurrent nasopharyngeal carcinoma. Head Neck 24 (8): 748-53, 2002.</Citation><Citation idx="9" PMID="11516866">Xiao J, Xu G, Miao Y: Fractionated stereotactic radiosurgery for 50 patients with recurrent or residual nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 51 (1): 164-70, 2001.</Citation></ReferenceSection></SummarySection><SummarySection id="_100"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (07/31/2014)</Title><Para id="_101">The PDQ cancer information summaries are reviewed regularly and updated as
new information becomes available.  This section describes the latest
changes made to this summary as of the date above.</Para><Para id="_280">Editorial changes were made to this summary.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062918#_AboutThis_1" url="http://www.cancer.gov/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of nasopharyngeal cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Nasopharyngeal Cancer Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Scharukh Jalisi, MD, FACS (Boston University Medical Center)</ListItem><ListItem>Minh Tam Truong, MD (Boston University Medical Center)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Nasopharyngeal Cancer Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/head-and-neck/hp/nasopharyngeal-treatment-pdq">http://www.cancer.gov/types/head-and-neck/hp/nasopharyngeal-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2014-07-31</DateLastModified></Summary>
